In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Eli Lilly has lined up another deal in the ... Novo Nordisk's long-acting growth hormone Sogroya works as well as Norditropin in a trio of paediatric growth disorders, with far fewer injections.

Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson ... the launch of a next-generation digital ecosystem for Growth Hormone Deficiency, a move that underscores its commitment to ...

Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck ... recently announced the launch of a next-generation digital ecosystem for Growth Hormone Deficiency, a move that ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly's potential Houston expansion could bring thousands of jobs and billions of dollars in investment to the area. Here ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...